Nirvana Life Sciences Inc.
NIRV
CNSX
| 07/31/2025 | 04/30/2025 | 01/31/2025 | 10/31/2024 | 07/31/2024 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | -31.33% | -44.18% | -60.81% | -54.48% | -49.84% |
| Depreciation & Amortization | -163.70% | -163.70% | -82.63% | -60.18% | -73.58% |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | -44.07% | -56.21% | -63.25% | -55.06% | -50.23% |
| Operating Income | 44.07% | 56.21% | 63.25% | 55.06% | 50.23% |
| Income Before Tax | 58.73% | 68.49% | 63.55% | 52.63% | 49.19% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | 58.73% | 68.49% | 63.55% | 52.63% | 49.19% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -105.88% | -109.09% | -85.71% | -54.29% | -48.48% |
| Net Income | 58.58% | 68.37% | 63.47% | 52.64% | 49.21% |
| EBIT | 44.07% | 56.21% | 63.25% | 55.06% | 50.23% |
| EBITDA | 51.31% | 55.17% | 62.40% | 52.64% | 49.39% |
| EPS Basic | 64.27% | 71.05% | 67.69% | 61.01% | 60.17% |
| Normalized Basic EPS | 54.33% | 67.06% | 72.59% | 64.30% | 62.94% |
| EPS Diluted | 64.27% | 71.05% | 67.69% | 61.01% | 60.17% |
| Normalized Diluted EPS | 54.33% | 67.06% | 72.59% | 64.30% | 62.94% |
| Average Basic Shares Outstanding | 99.60% | 6.81% | 8.29% | 18.01% | 29.63% |
| Average Diluted Shares Outstanding | 99.60% | 6.81% | 8.29% | 18.01% | 29.63% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |